According to our latest study on "Automated Cell Counters Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type and End User," the market is expected to grow from US$ 6,974.29 million in 2021 to US$ 10,365.95 million by 2028; it is estimated to grow at a CAGR of 5.9% from 2022 to 2028. The report highlights the key factors and trends impacting the market and focuses on prominent players and their strategies.

Research laboratories mainly focus on developing diagnostic and treatments for infectious and chronic diseases. Infectious diseases and clinical microbiology are fascinating and rapidly changing medical fields with ongoing complex challenges. In recent years, a real revolution in infection diagnosis has occurred due to the incorporation of a wide arsenal of techniques. Diagnostic stewardship is essential for the optimization of cell counter techniques and to accomplish their maximum efficiency and profitability. Countries across the globe are focusing on investing in research and development activities for the control of various infectious diseases. For instance, in India, the Department of Biotechnology (DBT), under the Ministry of Science & Technology, invests in the development of indigenous, reliable, rapid, sensitive, specific, cost-effective, and easy to use in a variety of settings diagnostic platforms and technologies, identifying potential targets for developing novel approaches to broad-spectrum interventions, and new strategies for developing immunotherapies, including those based on host responses.

Download Sample PDF Copy @ https://bit.ly/3SK8b2i

In addition, The Infectious Disease Research Institute (IDRI) is a nonprofit US scientific organization to develop vaccines, therapeutics, and diagnostics for various diseases in developing countries. The IDRI has been a partner in the MSD Fellowship for Global Health. MSD Fellows worked with IDRI on developing a global stakeholder engagement strategy and addressing issues associated with HIV R&D as part of the HIV Cure Initiative and developed a strategic plan for the production and commercialization of vaccines and bio therapeutics in African countries. This increase in research for the development of treatment of infectious diseases is driving the growth of the research laboratories segment.

Based on end user, the automated cell counters market is segmented into hospitals, research laboratories, diagnostic centers, and others. The hospital segment is likely to hold the largest share of the market in 2022. However, the research laboratories are expected to register the highest CAGR from 2022 to 2028. The hospital provides healthcare facilities through specialized scientific equipment. The team of trained staff is assigned to deal with the problems associated with modern medical science in the hospital and help restore normal body functions. Various medical research teams are constantly working to introduce innovative therapeutic technologies. Hospitals offer advanced treatment options for patients to treat chronic and infectious diseases. Further, growing government funding for hospitals and rising hospitalization of patients support the growth of the market for the hospitals segment.

Danaher & Agilent Technologies, Inc.–are Notable Market Players in Automated Cell Counters Market

Automated cell counters are machines that automatically count cells. The sample is loaded into an automated cell counter and is forced through a small tube while the automated cell counter uses optical or electrical impedance sensors to count how many cells passed through the tube.

Market Dynamics

The growth of the market is attributed to the prevalence of infectious and chronic diseases drives the overall market growth.  Additionally, the increase in drug discovery activities further enhance overall market growth during the forecast period.

Competitive Landscape

Market leaders operating in the automated cell counters market have undertaken various organic and inorganic growth strategies. The automated cell counters market majorly consists of players such as Eppendorf, Thermo Fischer Scientific, Countstar, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Chemometec A/S, ALIGNEDGENETICS, Beckman Coulter, Inc. (Danaher), Nanoentek, Olympus Corporation, MERCK KGaA, Sysmex Corporation, Agilent Technologies, Inc., Abbott, Nexcelom Bioscience LLC.

Several organic approaches, such as product launches, and expansion in the pharma ADMET testing market, have resulted in the growth of the market. Likewise, inorganic strategies such as mergers & acquisitions, and collaboration have helped the company to strengthen its revenue, which allows the company to hold a strong position in the market.  

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1–646–491–9876